Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HitGen has entered into a multi-year research collaboration and license agreement with Pfizer to build and screen novel DNA-encoded libraries (DELs) to potentially discover unique small molecule leads to be used in developing drugs.
Subscribe to our email newsletter
Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for Pfizer’s drug discovery efforts.
In addition, HitGen will screen their own DELs, consisting of billions of compounds, against a selected number of Pfizer’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to Pfizer for further research and development.
Pfizer will fund the research at HitGen.
Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen said: “We are delighted to announce this major collaboration with Pfizer, one of the leading multi-national biopharmaceutical companies in the world.
“We will work closely with Pfizer scientists to build proprietary DELs to support the discovery of a generation of new medicines to address unmet medical needs. This collaboration reflects HitGen’s capabilities, expertise, and flexibility to develop business models to meet the needs of our collaboration partners.
Dr. Tony Wood, Senior Vice President and Head of Medicinal Sciences, Pfizer said: “We are excited about our new collaboration with HitGen.
“We look forward to identifying new opportunities that will further expand our ability to identify new leads for multiple target families. The generation of proprietary DELs will leverage Pfizer’s parallel medicinal chemistry expertise and potentially accelerate the path of new medicines from idea to the clinic.”